What is vildagliptin tablets used for?
Vildagliptin is a DPP-4 inhibitor approved for the treatment of type 2 diabetes. Glucagon-like peptide-1 (GLP-1) is a hormone that is rapidly released from the intestine after eating. GLP-1 signals to the pancreas to increase insulin release, and reduce glucagon release, after a meal.
Is vildagliptin better than metformin?
Conclusions: Vildagliptin is an effective and well-tolerated treatment option in elderly patients with type 2 diabetes, demonstrating similar improvement in glycaemic control as metformin, with superior GI tolerability.
What is the difference between sitagliptin and vildagliptin?
The reason for the differences in drug efficacy (mean blood glucose level and MAGE) observed in this study is considered to be that sitagliptin 50 mg daily results in less than 70% suppression of DPP-4 activity over 24 h  whereas vildagliptin 50 mg twice daily results in 80% or greater suppression of DPP-4 activity …
What is difference between vildagliptin and glimepiride?
Vildagliptin significantly reduced body weight relative to glimepiride (mean [SE] change from baseline -0.23 [0.11] kg; between-group difference -1.79 kg; p < 0.001) and resulted in a 10-fold lower incidence of hypoglycaemia than glimepiride (1.7 vs. 16.2% of patients presenting at least one hypoglycaemic event; 39 vs.
Is vildagliptin safe for long term?
Conclusion: Vildagliptin as an add-on to insulin treatment for 24months was well tolerated and led to sustained reductions in HbA1c, the dose and number of insulin injections, and the risk of hypoglycemia.
Is vildagliptin safe for long-term?
Is vildagliptin safe?
Vildagliptin has been shown to be reasonably safe in clinical trials; however, long-term safety evaluations and clinical experience with the effects of DPP4 inhibition are needed. The DPP4 enzyme is found in a variety of tissues and is a substrate for a variety of hormones and peptides in the human body.
Does vildagliptin cause weight gain?
Vildagliptin does not cause any weight gain. In general, Vildagliptin is weight-neutral. But in patients with relatively low baseline glycemia, modest weight loss has been observed. The weight neutrality observed with vildagliptin is a class effect of DPP-4 inhibitors.
Why does vildagliptin not cause weight gain?
The low risk of hypoglycemia with vildagliptin, stemming from its glucose-dependent mechanism of action, likely contributes to this weight neutrality by obviating the “defensive eating” that can occur with exogenous insulin or glucose-independent insulin secretagogues.
Is vildagliptin safe for heart patients?
Conclusions: This large meta-analysis indicates that vildagliptin is not associated with an increased risk of adjudicated MACEs relative to comparators. Moreover, this analysis did not find a significant increased risk of HF in vildagliptin-treated patients.